Table 1.

Axitinib clinical efficacy by prior therapy and prognostic group

Clinical subgroup	Number of patients	PFSa hazard ratio (95% CI)
Prior sunitinib therapy	389	0.741 (0.574–0.958)
Prior cytokine therapy	251	0.462 (0.318–0.673)
MSKCC favorable risk	201	0.497 (0.326–0.758)
MSKCC intermediate risk	264	0.795 (0.578–1.094)
MSKCC poor risk	238	0.680 (0.491–0.941)
Heng favorable risk	145	0.701 (0.441–1.114)
Heng intermediate risk	461	0.644 (0.502–0.826)
Heng poor risk	71	0.860 (0.495–1.494)

Note:

^aHazard ratio for survival time comparison as against with sorafenib. Data from Rini et al.6

Abbreviations: PFS, progression-free survival; CI, confidence interval; MSKCC, Memorial Sloan-Kettering Cancer Center.